These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 23977117)

  • 1. Cerebral blood volume calculated by dynamic susceptibility contrast-enhanced perfusion MR imaging: preliminary correlation study with glioblastoma genetic profiles.
    Ryoo I; Choi SH; Kim JH; Sohn CH; Kim SC; Shin HS; Yeom JA; Jung SC; Lee AL; Yun TJ; Park CK; Park SH
    PLoS One; 2013; 8(8):e71704. PubMed ID: 23977117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-invasive prediction of p53 and Ki-67 labelling indices and O-6-methylguanine-DNA methyltransferase promoter methylation status in adult patients with isocitrate dehydrogenase wild-type glioblastomas using diffusion-weighted imaging and dynamic susceptibility contrast-enhanced perfusion-weighted imaging combined with conventional MRI.
    Xing Z; Huang W; Su Y; Yang X; Zhou X; Cao D
    Clin Radiol; 2022 Aug; 77(8):e576-e584. PubMed ID: 35469666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of methylguanine methyltransferase promoter methylation in glioblastoma using dynamic contrast-enhanced magnetic resonance and diffusion tensor imaging.
    Ahn SS; Shin NY; Chang JH; Kim SH; Kim EH; Kim DW; Lee SK
    J Neurosurg; 2014 Aug; 121(2):367-73. PubMed ID: 24949678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between dynamic susceptibility contrast perfusion MRI and genomic alterations in glioblastoma.
    Ozturk K; Soylu E; Cayci Z
    Neuroradiology; 2021 Nov; 63(11):1801-1810. PubMed ID: 33738509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting MGMT Promoter Methylation of Glioblastoma from Dynamic Susceptibility Contrast Perfusion: A Radiomic Approach.
    Crisi G; Filice S
    J Neuroimaging; 2020 Jul; 30(4):458-462. PubMed ID: 32374045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A clinicopathological and molecular analysis of glioblastoma multiforme with long-term survival.
    Das P; Puri T; Jha P; Pathak P; Joshi N; Suri V; Sharma MC; Sharma BS; Mahapatra AK; Suri A; Sarkar C
    J Clin Neurosci; 2011 Jan; 18(1):66-70. PubMed ID: 20888234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic dilemma of pseudoprogression in the treatment of newly diagnosed glioblastomas: the role of assessing relative cerebral blood flow volume and oxygen-6-methylguanine-DNA methyltransferase promoter methylation status.
    Kong DS; Kim ST; Kim EH; Lim DH; Kim WS; Suh YL; Lee JI; Park K; Kim JH; Nam DH
    AJNR Am J Neuroradiol; 2011 Feb; 32(2):382-7. PubMed ID: 21252041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different diagnostic values of imaging parameters to predict pseudoprogression in glioblastoma subgroups stratified by MGMT promoter methylation.
    Yoon RG; Kim HS; Paik W; Shim WH; Kim SJ; Kim JH
    Eur Radiol; 2017 Jan; 27(1):255-266. PubMed ID: 27048531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic examination performance by using microvascular leakage, cerebral blood volume, and blood flow derived from 3-T dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in the differentiation of glioblastoma multiforme and brain metastasis.
    Server A; Orheim TE; Graff BA; Josefsen R; Kumar T; Nakstad PH
    Neuroradiology; 2011 May; 53(5):319-30. PubMed ID: 20625709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebral blood volume analysis in glioblastomas using dynamic susceptibility contrast-enhanced perfusion MRI: a comparison of manual and semiautomatic segmentation methods.
    Jung SC; Choi SH; Yeom JA; Kim JH; Ryoo I; Kim SC; Shin H; Lee AL; Yun TJ; Park CK; Sohn CH; Park SH
    PLoS One; 2013; 8(8):e69323. PubMed ID: 23950891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of MGMT methylation and expression of MGMT, P53, EGFR, MDM2 and PTEN in glioblastoma multiforme.
    Limam S; Missaoui N; Abdessayed N; Mestiri S; Selmi B; Mokni M; Yacoubi MT
    Ann Biol Clin (Paris); 2019 Jun; 77(3):307-317. PubMed ID: 31131831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiogenomics of Glioblastoma: Machine Learning-based Classification of Molecular Characteristics by Using Multiparametric and Multiregional MR Imaging Features.
    Kickingereder P; Bonekamp D; Nowosielski M; Kratz A; Sill M; Burth S; Wick A; Eidel O; Schlemmer HP; Radbruch A; Debus J; Herold-Mende C; Unterberg A; Jones D; Pfister S; Wick W; von Deimling A; Bendszus M; Capper D
    Radiology; 2016 Dec; 281(3):907-918. PubMed ID: 27636026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival.
    Eoli M; Menghi F; Bruzzone MG; De Simone T; Valletta L; Pollo B; Bissola L; Silvani A; Bianchessi D; D'Incerti L; Filippini G; Broggi G; Boiardi A; Finocchiaro G
    Clin Cancer Res; 2007 May; 13(9):2606-13. PubMed ID: 17473190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural and advanced imaging in predicting MGMT promoter methylation of primary glioblastoma: a region of interest based analysis.
    Han Y; Yan LF; Wang XB; Sun YZ; Zhang X; Liu ZC; Nan HY; Hu YC; Yang Y; Zhang J; Yu Y; Sun Q; Tian Q; Hu B; Xiao G; Wang W; Cui GB
    BMC Cancer; 2018 Feb; 18(1):215. PubMed ID: 29467012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.
    Jha P; Suri V; Jain A; Sharma MC; Pathak P; Jha P; Srivastava A; Suri A; Gupta D; Chosdol K; Chattopadhyay P; Sarkar C
    Neurosurgery; 2010 Dec; 67(6):1681-91. PubMed ID: 21107199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of molecular biomarkers in glioblastoma.
    Ang C; Guiot MC; Ramanakumar AV; Roberge D; Kavan P
    Can J Neurol Sci; 2010 Sep; 37(5):625-30. PubMed ID: 21059509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment Dynamic Susceptibility Contrast MRI Perfusion in Glioblastoma: Prediction of EGFR Gene Amplification.
    Gupta A; Young RJ; Shah AD; Schweitzer AD; Graber JJ; Shi W; Zhang Z; Huse J; Omuro AM
    Clin Neuroradiol; 2015 Jun; 25(2):143-50. PubMed ID: 24474262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathology: commonly monitored glioblastoma markers: EFGR, EGFRvIII, PTEN, and MGMT.
    Camara-Quintana JQ; Nitta RT; Li G
    Neurosurg Clin N Am; 2012 Apr; 23(2):237-46, viii. PubMed ID: 22440867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Initial Area Under the Curve Derived from Dynamic Contrast-Enhanced MRI Improves Prognosis Prediction in Glioblastoma with Unmethylated
    Choi YS; Ahn SS; Lee HJ; Chang JH; Kang SG; Kim EH; Kim SH; Lee SK
    AJNR Am J Neuroradiol; 2017 Aug; 38(8):1528-1535. PubMed ID: 28642265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamic Contrast-Enhanced T1-Weighted Perfusion Magnetic Resonance Imaging Identifies Glioblastoma Immunohistochemical Biomarkers via Tumoral and Peritumoral Approach: A Pilot Study.
    Ozturk K; Soylu E; Tolunay S; Narter S; Hakyemez B
    World Neurosurg; 2019 Aug; 128():e195-e208. PubMed ID: 31003026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.